{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ofatumumab+placebo", "query": { "intervention": "Ofatumumab placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T21:52:39.162Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02792231", "title": "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Scelrosis" ], "interventions": [ { "name": "Ofatumumab subcutaneous injection", "type": "DRUG" }, { "name": "Teriflunomide-matching placebo capsules", "type": "DRUG" }, { "name": "Teriflunomide capsule", "type": "DRUG" }, { "name": "Matching placebo of ofatumumab subcutaneous injections", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 955, "start_date": "2016-08-26", "completion_date": "2020-10-22", "has_results": true, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-09-22T21:52:39.162Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Basalt", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02792231" }, { "nct_id": "NCT00686868", "title": "Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "placebo", "type": "OTHER" }, { "name": "ofatumumab", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2008-06-13", "completion_date": "2011-05-02", "has_results": false, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-09-22T21:52:39.162Z", "location_count": 2, "location_summary": "Anniston, Alabama • Miramar, Florida", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00686868" }, { "nct_id": "NCT04926818", "title": "Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis (MS)" ], "interventions": [ { "name": "Fingolimod", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Siponimod", "type": "DRUG" }, { "name": "Fingolimod placebo", "type": "OTHER" }, { "name": "Siponimod placebo", "type": "OTHER" }, { "name": "Ofatumumab placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 129, "start_date": "2021-10-05", "completion_date": "2031-02-28", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-22T21:52:39.162Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04926818" }, { "nct_id": "NCT01457924", "title": "Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ofatumumab 3mg", "type": "DRUG" }, { "name": "Ofatumumab 30mg", "type": "DRUG" }, { "name": "Ofatumumab 60mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 232, "start_date": "2011-11-01", "completion_date": "2015-06-10", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-09-22T21:52:39.162Z", "location_count": 16, "location_summary": "Cullman, Alabama • Fullerton, California • Fairfield, Connecticut + 13 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Sunrise", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01457924" }, { "nct_id": "NCT01920477", "title": "Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pemphigus Vulgaris" ], "interventions": [ { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 35, "start_date": "2013-08-13", "completion_date": "2018-01-11", "has_results": true, "last_update_posted_date": "2019-06-06", "last_synced_at": "2026-09-22T21:52:39.162Z", "location_count": 7, "location_summary": "Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01920477" }, { "nct_id": "NCT02792218", "title": "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Ofatumumab subcutaneous injection", "type": "DRUG" }, { "name": "Teriflunomide-matching placebo capsules", "type": "DRUG" }, { "name": "Teriflunomide capsule", "type": "DRUG" }, { "name": "Matching placebo of ofatumumab subcutaneous injections", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 930, "start_date": "2016-09-20", "completion_date": "2020-07-20", "has_results": true, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-09-22T21:52:39.162Z", "location_count": 56, "location_summary": "Phoenix, Arizona • Berkeley, California • Fullerton, California + 50 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02792218" }, { "nct_id": "NCT00655824", "title": "Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "ofatumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2008-01-01", "completion_date": "2013-03-19", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-09-22T21:52:39.162Z", "location_count": 4, "location_summary": "Los Angeles, California • Fort Lauderdale, Florida • New York, New York + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Duncansville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655824" } ] }